For the treatment of Haemophilia A and B, Biotest AG manufactures two preparations which derive from human plasma and are designed for intravenous injection.
Biotest produces several antibody concentrates from human blood plasma which are available as ready-to-use solutions. Biotest offers the IVIG preparation Intratect and different hyperimmunoglobulins with increased antibody titers against cytomegaloviruses (CMV), hepatitis B viruses (HBV) or varicella zoster viruses (VZV).
Biotest produces several human blood plasma derived concentrates for intensive care medicines. These include Pentaglobin, an IgM enriched immunoglobulin, and other intravenously administered solutions, for the treatment of severe bacterial infections, coagulation disorders, and volume- or protein-substitution.
21.07.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services incl ...
[More]
20.07.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services incl ...
[More]
16.07.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services incl ...
[More]
10.06.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services incl ...
[More]
08.06.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services incl ...
[More]
26.05.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services incl ...
[More]
08.05.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services incl ...
[More]
08.05.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services incl ...
[More]
06.04.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services incl ...
[More]
03.04.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services incl ...
[More]
30.03.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services incl ...
[More]
Announcement according to Article 17 European Market Abuse Regulation (MAR)Biotest exceeds already raised EBIT guidanceDreieich, 26 February 2020. According to preliminary and unaudited figures, the B ...
[More]
15.01.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services incl ...
[More]
17.12.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services incl ...
[More]
11.12.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services incl ...
[More]
Announcement according to Article 17 European Market Abuse Regulation (MAR)Biotest AG increases GuidanceDreieich, 4 December 2019. Following the evaluation of the current business situation, the Manag ...
[More]
